Novartis Prevails In Patent Suit Vs. Dr. Reddy's Over Lamisil

Law360, New York (September 3, 2004, 12:00 AM EDT) -- Swiss drug giant Novartis has fended off a patent challenge from Indian generic maker Dr. Reddy’s against its widely prescribed oral antifungant Lamisil.

Dr. Reddy's Laboratories withdrew its challenge to the Lamisil patent and conceded that it is valid, enforceable and had been infringed by the Indian generic maker, Novartis said Friday.

Dr. Reddy's said it pulled its legal challenge “because the time needed to obtain a favorable Federal Circuit decision prior to patent expiration would not be met.”

Novartis filed the lawsuit the U.S. District...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.